Subscribe

Original Research

When an Outcome Is Overdetermined: Nonadherence, Utilization, and the Impetus for Research in COPD
An Ounce of Prevention Is Not a Choice a Patient Gets to Make for Late-Stage Cancer
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
You Cannot Manage What You Cannot Measure
A Teachable Moment in Health Benefits Design
Counting on a Run of Value-Based Benefit Design
Response-Guided Therapy an Appropriate Tool for Evaluating Treatment Protocols and Costs of Drug Therapies
Employers’ Obesity Initiatives in the Workplace: A Wakeup Call for Health Plans
Benefit Management Considerations for BPH Medications: Single Agent or Combination Therapy?
A Collaborative Approach to Drug Selection, Driven by Clinical Outcomes Excellence
Page 7 of 8
Results 61 - 70 of 76
Copyright © Engage Healthcare Communications, LLC. All rights reserved.